目的探讨三阴乳腺癌的临床特征,寻求三阴乳腺癌经手术及化疗等治疗的预后及特点。方法采取回顾性方式分析明光市人民医院15例三阴乳腺癌患者的临床资料、治疗方法、病理特点。结果 15例乳腺癌患者肿块大小1~4 cm,术后病理ER(-),PR(-),HER-2(-),CK5/6(+)12例(80.0%),其中腋窝淋巴结转移13例(86.7%)。15例患者均行乳腺癌改良根治术,患者术后均给予TEC方案化疗,其中2例患者术后1年内死亡,4例患者术后1~2年内出现胸壁复发,行局部肿块切除,更换化疗方案再次给予化疗,5例患者术后2年内出现肺、肝、脑或全身性骨转移,更换方案化疗。结论三阴乳腺癌因缺乏内分泌及抗HER2治疗的靶点,目前尚无针对性的标准治疗方案,它是恶性程度高、死亡率高的恶性肿瘤,易出现局部复发和远处转移且高峰期在术后1~2年,由于此类患者复发风险明显较高,且没有靶向治疗可选择,因此任何风险的降低必须源于化疗。 Objective To investigate the clinical features of triple-negative breast cancer and to seek the prognosis and characteristics of triple-negative breast cancer after surgery and chemotherapy. Methods The retrospective analysis of 15 patients with triple-negative breast cancer in Mingguang People’s Hospital clinical data, treatment methods, pathological features. Results The size of the tumors in patients with breast cancer was 1 ~ 4 cm in size and 12 (80.0%) were ER (-), PR (-), HER-2 and CK5 / 13 cases (86.7%). Fifteen patients underwent radical mastectomy for breast cancer. Two patients were treated with TEC regimen after the operation. Two patients died within one year after operation. Four patients developed chest wall recurrence within one to two years after operation. Local resection and chemotherapy The regimen was given chemotherapy again. Five patients had lung, liver, brain or systemic bone metastases within 2 years after operation, and replaced the regimen with chemotherapy. Conclusion Due to the lack of endocrine and anti-HER2 therapeutic targets, there is no standard treatment for triple-negative breast cancer. It is a malignant tumor with high degree of malignancy and high mortality. It is prone to local recurrence and distant metastasis and the peak period One to two years after surgery, any reduction in risk must be attributed to chemotherapy because of the significantly higher risk of relapse and the absence of targeted therapy.